253 related articles for article (PubMed ID: 30833419)
1. Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.
Benito-Jardón L; Díaz-Martínez M; Arellano-Sánchez N; Vaquero-Morales P; Esparís-Ogando A; Teixidó J
Cancer Res; 2019 May; 79(9):2244-2256. PubMed ID: 30833419
[TBL] [Abstract][Full Text] [Related]
2. ERK5 is activated by oncogenic BRAF and promotes melanoma growth.
Tusa I; Gagliardi S; Tubita A; Pandolfi S; Urso C; Borgognoni L; Wang J; Deng X; Gray NS; Stecca B; Rovida E
Oncogene; 2018 May; 37(19):2601-2614. PubMed ID: 29483645
[TBL] [Abstract][Full Text] [Related]
3. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
[TBL] [Abstract][Full Text] [Related]
4. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAF
Lee B; Sahoo A; Sawada J; Marchica J; Sahoo S; Layng FIAL; Finlay D; Mazar J; Joshi P; Komatsu M; Vuori K; de Jong PR; Ray A; Perera RJ
J Invest Dermatol; 2021 Feb; 141(2):385-394. PubMed ID: 32888955
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.
Zhou C; Nitschke AM; Xiong W; Zhang Q; Tang Y; Bloch M; Elliott S; Zhu Y; Bazzone L; Yu D; Weldon CB; Schiff R; McLachlan JA; Beckman BS; Wiese TE; Nephew KP; Shan B; Burow ME; Wang G
Breast Cancer Res; 2008; 10(6):R105. PubMed ID: 19087274
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE
J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004
[TBL] [Abstract][Full Text] [Related]
8. The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer.
Cristea S; Coles GL; Hornburg D; Gershkovitz M; Arand J; Cao S; Sen T; Williamson SC; Kim JW; Drainas AP; He A; Cam LL; Byers LA; Snyder MP; Contrepois K; Sage J
Cancer Res; 2020 Mar; 80(6):1293-1303. PubMed ID: 31969375
[TBL] [Abstract][Full Text] [Related]
9. The Hedgehog-GLI Pathway Regulates MEK5-ERK5 Expression and Activation in Melanoma Cells.
Tusa I; Gagliardi S; Tubita A; Pandolfi S; Menconi A; Lulli M; Dello Sbarba P; Stecca B; Rovida E
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681917
[TBL] [Abstract][Full Text] [Related]
10. MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.
Antoon JW; Martin EC; Lai R; Salvo VA; Tang Y; Nitzchke AM; Elliott S; Nam SY; Xiong W; Rhodes LV; Collins-Burow B; David O; Wang G; Shan B; Beckman BS; Nephew KP; Burow ME
PLoS One; 2013; 8(8):e69291. PubMed ID: 23950888
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.
Hoang VT; Matossian MD; La J; Hoang K; Ucar DA; Elliott S; Burks HE; Wright TD; Patel S; Bhatt A; Phamduy T; Chrisey D; Buechlein A; Rusch DB; Nephew KP; Anbalagan M; Rowan B; Cavanaugh JE; Flaherty PT; Miele L; Collins-Burow BM; Burow ME
J Cell Biochem; 2021 Aug; 122(8):835-850. PubMed ID: 33876843
[TBL] [Abstract][Full Text] [Related]
12. MEK5 and ERK5 are localized in the nuclei of resting as well as stimulated cells, while MEKK2 translocates from the cytosol to the nucleus upon stimulation.
Raviv Z; Kalie E; Seger R
J Cell Sci; 2004 Apr; 117(Pt 9):1773-84. PubMed ID: 15075238
[TBL] [Abstract][Full Text] [Related]
13. Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton.
Barros JC; Marshall CJ
J Cell Sci; 2005 Apr; 118(Pt 8):1663-71. PubMed ID: 15797923
[TBL] [Abstract][Full Text] [Related]
14. YAP promotes myogenic differentiation
Chen TH; Chen CY; Wen HC; Chang CC; Wang HD; Chuu CP; Chang CH
FASEB J; 2017 Jul; 31(7):2963-2972. PubMed ID: 28356344
[TBL] [Abstract][Full Text] [Related]
15. PB1 domain-dependent signaling complex is required for extracellular signal-regulated kinase 5 activation.
Nakamura K; Uhlik MT; Johnson NL; Hahn KM; Johnson GL
Mol Cell Biol; 2006 Mar; 26(6):2065-79. PubMed ID: 16507987
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic signaling of MEK5-ERK5.
Hoang VT; Yan TJ; Cavanaugh JE; Flaherty PT; Beckman BS; Burow ME
Cancer Lett; 2017 Apr; 392():51-59. PubMed ID: 28153789
[TBL] [Abstract][Full Text] [Related]
17. Non-redundant function of the MEK5-ERK5 pathway in thymocyte apoptosis.
Sohn SJ; Lewis GM; Winoto A
EMBO J; 2008 Jul; 27(13):1896-906. PubMed ID: 18548009
[TBL] [Abstract][Full Text] [Related]
18. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
19. ERK5 signalling in prostate cancer promotes an invasive phenotype.
Ramsay AK; McCracken SR; Soofi M; Fleming J; Yu AX; Ahmad I; Morland R; Machesky L; Nixon C; Edwards DR; Nuttall RK; Seywright M; Marquez R; Keller E; Leung HY
Br J Cancer; 2011 Feb; 104(4):664-72. PubMed ID: 21266977
[TBL] [Abstract][Full Text] [Related]
20. Specificity of Phosphorylation Responses to Mitogen Activated Protein (MAP) Kinase Pathway Inhibitors in Melanoma Cells.
Basken J; Stuart SA; Kavran AJ; Lee T; Ebmeier CC; Old WM; Ahn NG
Mol Cell Proteomics; 2018 Apr; 17(4):550-564. PubMed ID: 29255136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
